| dc.creator | JUAN LUIS PICHARDO MOLINA | |
| dc.date | 2015-01-01 | |
| dc.date | info:eu-repo/date/embargoEnd/2025-01-01 | |
| dc.date.accessioned | 2023-07-21T15:15:37Z | |
| dc.date.available | 2023-07-21T15:15:37Z | |
| dc.identifier | http://cio.repositorioinstitucional.mx/jspui/handle/1002/1042 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/7725810 | |
| dc.description | Imatinib is the standard first line treatment for chronic myeloid leukemia (CML). Owing to dose-related toxicities of Imatinib such as neutropenia, there is scope for treatment optimization through therapeutic drug monitoring (TDM). Trough concentration of 1 μg/mL is considered the therapeutic threshhold. Existing methods for the detection of Imatinib in plasma are limited by long read out time and expensive instrumentation. Hence, Raman spectroscopy was explored as a rapid and objective tool for monitoring Imatinib concentration. Three approaches: conventional Raman spectroscopy (CRS), Drop coating deposition Raman (DCDR) spectroscopy and surface-enhanced Raman spectroscopy (SERS) were employed to detect the required trough concentration of 1 μg/mL and above. Detection of therapeutically relevant concentrations (1 μg/mL) using SERS and suitable nanoparticle substrates has been demonstrated. Prospectively, rigorous validation using clinical samples is necessary to confirm the utility of this approach in routine clinical usage. | |
| dc.format | application/pdf | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
| dc.subject | info:eu-repo/classification/cti/1 | |
| dc.subject | info:eu-repo/classification/cti/1 | |
| dc.title | Raman spectroscopy for detection of imatinib in plasma: A proof of concept | |
| dc.type | info:eu-repo/semantics/article | |
